However, in the case of treatment with 131I for patients with differentiated thyroid carcinoma [124,125], 177Lu-DOTATATE for patients with neuroendocrine tumors [126], and 177Lu-PSMA for patients with PCa [127], a time- and dose-dependent induction of DSB has been observed, as evidenced by the formation of γ-H2AX and 53BP1 nuclear foci. The gene discussed is TP53BP1; the disease is posterior cortical atrophy.